New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada

Published:April 16, 2022DOI:



      Recent diabetes guidelines call for prescribing sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) for end-organ indications (cardiovascular disease [CVD], heart failure and chronic kidney disease) and for primary prevention of CVD in adults with multiple risk factors. Our aim was to assess the effect of new guidelines on the prevalence of SGLT2i/GLP-1RA–eligible adults, and their current rates of SGLT2i/GLP-1RA use.


      A cross-sectional study was conducted of Canadian adults (age ≥18 years) with diabetes on June 30, 2020, using electronic medical record data from primary care practices in 5 provinces (Alberta, Manitoba, Newfoundland, Ontario and Québec). Indications were determined from comorbidities, lab values and cardiovascular risk factors.


      End-organ indications were present in 34.1% of adults for SGLT2i and in 17.1% for GLP-1RA (CVD only). Rates of SGLT2i and GLP-1RA use were only 14.0% and 4.3%, respectively, in those with end-organ indications. The majority of these individuals had glycated hemoglobin ≤7.0%. The combination of end-organ and primary prevention indications increased eligibility for SGLT2i to 62.6%, and for GLP-1RA to 59.1%.


      The implications of this sizeable reclassification of adults as SGLT2i/GLP-1RA indicated on health-care budgets and cost-effectiveness requires further study. In the meantime, targeted efforts are necessary to improve SGLT2i/GLP-1RA use in those with end-organ indications that have robust evidence of cardiovascular and kidney benefit from newer agents.



      Les récentes lignes directrices en matière de diabète préconisent de prescrire les inhibiteurs du cotransporteur sodium-glucose de type 2 (iSGLT-2) et les agonistes des récepteurs du GLP-1 (glucagon-like peptide-1, AR-GLP-1) lors d’indications d’atteintes aux organes cibles (maladie cardiovasculaire [MCV], insuffisance cardiaque et insuffisance rénale chronique) et de prévention primaire de MCV chez les adultes qui ont de multiples facteurs de risque. Notre objectif était d’évaluer les répercussions des nouvelles lignes directrices sur la proportion d’adultes admissibles aux iSGLT-2/AR-GLP-1, et leurs taux actuels d’utilisation des iSGLT-2/AR-GLP-1.


      Il s’agissait d’une étude transversale auprès d’adultes canadiens (≥ 18 ans) diabétiques au 30 juin 2020 à partir des données des dossiers médicaux électroniques de cabinets en soins primaires de 5 provinces (Alberta, Manitoba, Terre-Neuve, Ontario et Québec). Les indications ont été déterminées à partir des maladies associées, des résultats de laboratoire et des facteurs de risque cardiovasculaire.


      Les iSGLT-2 étaient indiqués chez 34,1 % des adultes qui présentaient des atteintes aux organes cibles, et les AR-GLP-1, chez 17,1 % qui présentaient seulement une MCV. Les patients chez lesquels les iSGLT-2 et les AR-GLP-1 étaient indiqués dans le traitement des atteintes aux organes cibles, les taux d’utilisation étaient respectivement de 14,0 % et de 4,3 % seulement. La plupart de ces individus avaient une hémoglobine glyquée ≤ 7,0 %. La combinaison des indications d’atteintes aux organes cibles et de prévention primaire a fait accroître l’admissibilité aux iSGLT-2 à 62,6 % et aux AR-GLP-1 à 59,1 %.


      Des études complémentaires sur les répercussions de cette importante reclassification des adultes admissibles aux iSGLT-2 et aux AR-GLP-1 sur les budgets et l’efficience en soins de santé sont nécessaires. Entre-temps, il faut tout mettre en œuvre pour améliorer l’utilisation des iSGLT-2/AR-GLP-1 lors d’atteintes aux organes cibles chez les individus qui satisfont aux indications, et qui démontrent des avantages cardiovasculaires et rénaux réels des nouveaux médicaments.


      Mots clés

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Giugliano D.
        • Maiorino M.
        • Bellastella G.
        • et al.
        GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.
        Diabetes Obes Metab. 2019; 21: 2576-2580
        • Kristensen S.
        • Rorth R.
        • Jhund P.
        • et al.
        Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet Diabetes Endocrinol. 2019; 7: 776-785
        • Perkovic V.
        • Jardine M.
        • Neal B.
        • et al.
        Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
        N Engl J Med. 2019; 380: 2295-2306
        • Zelniker T.
        • Wiviott S.
        • Raz I.
        • et al.
        SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet. 2019; 393: 31-39
        • Gerstein H.
        • Colhoun H.
        • Dagenais G.
        • et al.
        Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial.
        Lancet. 2019; 394: 121-130
        • Wiviott S.
        • Raz I.
        • Bonaca M.
        • et al.
        Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2019; 380: 347-357
        • Lipscombe L.
        • Butalia S.
        • et al.
        • Diabetes Canada Clinical Practice Guidelines Expert Committee
        Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update.
        Can J Diabetes. 2020; 44: 575-591
        • Canadian Diabetes Association Clinical Practice Guidelines Expert Committee
        Pharmacologic management of type 2 diabetes: 2016 interim update.
        Can J Diabetes. 2016; 40: 484-486
        • McCoy R.
        • Lipska K.
        • Van Houten H.
        • et al.
        Paradox of glycemic management: Multimorbidity, glycemic control, and high-risk medication use among adults with diabetes.
        BMJ Open Diabetes Res Care. 2020; 8e001007
        • Horii T.
        • Oikawa Y.
        • Kunisada N.
        • et al.
        Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: A nationwide cohort study.
        BMJ Open Diabetes Res Care. 2020; 8e001856
        • de Heer J.
        • Holst J.
        Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1.
        Diabetes. 2007; 56: 438-443
        • Caparrotta T.
        • Blackbourn L.
        • McGurnaghan S.
        • et al.
        Prescribing paradigm shift? Applying the 2019 European Society of Cardiology–led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland.
        Diabetes Care. 2020; 43: 2034-2041
        • CPCSSN Team
        Case Definitions: Canadian Primary Care Sentinel Surveillance Network (CPCSSN), version 2020-Q2.
        • Garies S.
        • Birtwhistle R.
        • Drummond N.
        • et al.
        Data resource profile: National electronic medical record data from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN).
        Int J Epidemiol. 2017; 46 (1091–2f)
        • Queenan J.
        • Williamson T.
        • Khan S.
        • et al.
        Representativeness of patients and providers in the Canadian Primary Care Sentinel Surveillance Network: A cross-sectional study.
        CMAJ Open. 2016; 4: E28-E32
        • Williamson T.
        • Green M.
        • Birtwhistle R.
        • et al.
        Validating the 8 CPCSSN case definitions for chronic disease surveillance in a primary care database of electronic health records.
        Ann Fam Med. 2014; 12: 367-372
        • LeBlanc A.
        • Gao Y.
        • McRae L.
        • et al.
        At-a-glance---twenty years of diabetes surveillance using the Canadian Chronic Disease Surveillance System.
        Health Promot Chronic Dis Prev Can. 2019; 39: 306-309
        • Greiver M.
        • Williamson T.
        • Barber D.
        • et al.
        Prevalence and epidemiology of diabetes in Canadian primary care practices: A report from the Canadian Primary Care Sentinel Surveillance Network.
        Can J Diabetes. 2014; 38: 179-185
        • American Diabetes Association
        9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes---2020.
        Diabetes Care. 2020; 43: S98-S110
        • Cosentino F.
        • Grant P.J.
        • Aboyans V.
        • et al.
        2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
        Eur Heart J. 2020; 41: 255-323
        • Buse J.
        • Wexler D.
        • Tsapas A.
        • et al.
        2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
        Diabetes Care. 2020; 43: 487-493
        • Vijh R.
        • Wong S.
        • Grandy M.
        • et al.
        Identifying heart failure in patients with chronic obstructive lung disease through the Canadian Primary Care Sentinel Surveillance Network in British Columbia: A case derivation study.
        CMAJ Open. 2021; 9: E376-E383
        • Tu K.
        • Mitiku T.
        • Lee D.
        • et al.
        Validation of physician billing and hospitalization data to identify patients with ischemic heart disease using data from the Electronic Medical Record Administrative data Linked Database (EMRALD).
        Can J Cardiol. 2010; 26: e225-e228
        • McCormick N.
        • Bhole V.
        • Lacaille D.
        • et al.
        Validity of diagnostic codes for acute stroke in administrative databases: A systematic review.
        PLoS One. 2015; 10e0135834
        • Tu K.
        • Wang M.
        • Young J.
        • et al.
        Validity of administrative data for identifying patients who have had a stroke or transient ischemic attack using EMRALD as a reference standard.
        Can J Cardiol. 2013; 29: 1388-1394
        • Ivers N.
        • Pylypenko B.
        • Tu K.
        Identifying patients with ischemic heart disease in an electronic medical record.
        J Prim Care Community Health. 2011; 2: 49-53
        • Farahani P.
        • Khan S.
        • Oatway M.
        • et al.
        Exploring the distribution of prescription for sulfonylureas in patients with type 2 diabetes according to cardiovascular risk factors within a Canadian primary care setting.
        J Popul Ther Clin Pharmacol. 2015; 22: e228-e236
        • Bello A.
        • Ronksley P.
        • Tangri N.
        • et al.
        Quality of chronic kidney disease management in canadian primary care.
        JAMA Netw Open. 2019; 2e1910704
        • Greiver M.
        • Kalia S.
        • Moineddin R.
        Impact of the diabetes Canada guideline dissemination strategy on dispensed vascular protective medications for older patients in Ontario, Canada: A linked EMR and administrative data study.
        BMC Health Serv Res. 2020; 20: 370
        • Rigobon A.
        • Kalia S.
        • Nichols J.
        • et al.
        Impact of the Diabetes Canada guideline dissemination strategy on the prescription of vascular protective medications: A retrospective cohort study, 2010–2015.
        Diabetes Care. 2019; 42: 148-156
        • Tu K.
        • Mitiku T.
        • Ivers N.
        • et al.
        Evaluation of Electronic Medical Record Administrative data Linked Database (EMRALD).
        Am J Manag Care. 2014; 20: e15-e21
        • Milder T.
        • Stocker S.
        • Baysari M.
        • et al.
        Prescribing of SGLT2 inhibitors in primary care: A qualitative study of general practitioners and endocrinologists.
        Diabetes Res Clin Pract. 2021; 180109036
        • Kramer C.
        • Zinman B.
        • Gross J.
        • et al.
        Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: Systematic review and meta-analysis.
        BMJ. 2013; 346: f1654
        • Pearson G.
        • Thanassoulis G.
        • Anderson T.
        2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults.
        Can J Cardiol. 2021; 37: 1129-1150
        • Mortensen M.
        • Nordestgaard B.
        Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat.
        JAMA Cardiol. 2019; 4: 1131-1138
        • Greiver M.
        • Havard A.
        • Bowles J.
        • et al.
        Trends in diabetes medication use in Australia, Canada, England, and Scotland: A repeated cross-sectional analysis in primary care.
        Br J Gen Pract. 2021; 71: e209-e218
        • Xu G.
        • Liu B.
        • Sun Y.
        • et al.
        Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: Population based study.
        BMJ. 2018; 362: k1497
        • Schernthaner G.
        • Shehadeh N.
        • Ametov A.
        • et al.
        Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
        Cardiovasc Diabetol. 2020; 19: 185